Skip to content

Study · Non-randomized trial · n = 24 · 2026

6 results

Slipped Capital Femoral Epiphysis during Vosoritide Therapy for Short Stature: A Case Series.

Kanakatti Shankar R, Oetgen ME, Martin BD, Shafaei N, Pitner K, Dauber A

Hormone research in paediatrics1 Sept 2026

PMID42678892 (opens in a new tab)DOI10.1159/hrp/adaag011 (opens in a new tab)PepBankPUB-42678892
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    No SCFE occurred in the 24 participants with hypochondroplasia during vosoritide therapy.

    In plain wordsNo SCFE occurred in the 24 participants with hypochondroplasia during vosoritide therapy.

    Peptide
    Vosoritide
    Outcome
    Not applicableSCFE in hypochondroplasia
    Study

    n = 24

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the basket trial, SCFE was observed in 2/12 participants with ACAN mutations, 1/11 with RASopathy but not in the 7 participants with NPR2 mutations or 24 with hypochondroplasia.
    1 context sentence
    Summary · context
    We report 5 participants from two investigator-initiated, single center, phase II, prospective, open label clinical trials of vosoritide (NCT04219007 Basket trial including patients with RASopathies, Aggrecan mutations (ACAN) and NPR2 deficiency and NCT05849389 in girls with Turner syndrome) who developed SCFE.
  2. 02HumanNon-randomized trialSafety outcome

    SCFE occurred in 2/12 participants with ACAN mutations during vosoritide therapy.

    In plain wordsSCFE occurred in 2/12 participants with ACAN mutations during vosoritide therapy.

    Peptide
    Vosoritide
    Outcome
    Not applicableSCFE in ACAN mutations
    Study

    n = 12

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Participants with SCFE
    2 participants
    ACAN mutations, of 12

    Source sentences

    Summary
    In the basket trial, SCFE was observed in 2/12 participants with ACAN mutations, 1/11 with RASopathy but not in the 7 participants with NPR2 mutations or 24 with hypochondroplasia.
    1 context sentence
    Summary · context
    We report 5 participants from two investigator-initiated, single center, phase II, prospective, open label clinical trials of vosoritide (NCT04219007 Basket trial including patients with RASopathies, Aggrecan mutations (ACAN) and NPR2 deficiency and NCT05849389 in girls with Turner syndrome) who developed SCFE.
  3. 03HumanNon-randomized trialSafety outcome

    SCFE occurred in 1/11 participants with RASopathy during vosoritide therapy.

    In plain wordsSCFE occurred in 1/11 participants with RASopathy during vosoritide therapy.

    Peptide
    Vosoritide
    Outcome
    Not applicableSCFE in RASopathy
    Study

    n = 11

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Participants with SCFE
    1 participants
    RASopathy, of 11

    Source sentences

    Summary
    In the basket trial, SCFE was observed in 2/12 participants with ACAN mutations, 1/11 with RASopathy but not in the 7 participants with NPR2 mutations or 24 with hypochondroplasia.
    1 context sentence
    Summary · context
    We report 5 participants from two investigator-initiated, single center, phase II, prospective, open label clinical trials of vosoritide (NCT04219007 Basket trial including patients with RASopathies, Aggrecan mutations (ACAN) and NPR2 deficiency and NCT05849389 in girls with Turner syndrome) who developed SCFE.
  4. 04HumanNon-randomized trialSafety outcome

    No SCFE occurred in the 7 participants with NPR2 mutations during vosoritide therapy.

    In plain wordsNo SCFE occurred in the 7 participants with NPR2 mutations during vosoritide therapy.

    Peptide
    Vosoritide
    Outcome
    Not applicableSCFE in NPR2 mutations
    Study

    n = 7

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the basket trial, SCFE was observed in 2/12 participants with ACAN mutations, 1/11 with RASopathy but not in the 7 participants with NPR2 mutations or 24 with hypochondroplasia.
    1 context sentence
    Summary · context
    We report 5 participants from two investigator-initiated, single center, phase II, prospective, open label clinical trials of vosoritide (NCT04219007 Basket trial including patients with RASopathies, Aggrecan mutations (ACAN) and NPR2 deficiency and NCT05849389 in girls with Turner syndrome) who developed SCFE.
  5. 05HumanNon-randomized trialSafety outcome

    SCFE occurred in 2/5 participants with Turner syndrome receiving vosoritide.

    In plain wordsSCFE occurred in 2/5 participants with Turner syndrome receiving vosoritide.

    Peptide
    Vosoritide
    Outcome
    Not applicableSCFE in Turner syndrome
    Study

    n = 5

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Participants with SCFE
    2 participants
    Turner syndrome trial, of 5

    Source sentences

    Summary
    In the Turner syndrome trial, 2/5 participants receiving vosoritide developed SCFE.
    1 context sentence
    Summary · context
    We report 5 participants from two investigator-initiated, single center, phase II, prospective, open label clinical trials of vosoritide (NCT04219007 Basket trial including patients with RASopathies, Aggrecan mutations (ACAN) and NPR2 deficiency and NCT05849389 in girls with Turner syndrome) who developed SCFE.
  6. 06HumanNon-randomized trialSafety outcome

    All 5 vosoritide-treated participants with SCFE presented with the rare valgus type after more than 12 months of treatment.

    In plain wordsAll 5 vosoritide-treated participants with SCFE had the rare valgus type after more than 12 months of treatment.

    Peptide
    Vosoritide
    Outcome
    Not applicableValgus SCFE presentation
    Study

    n = 5

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · >12 monthsAs given in this study (human).

    Measurements

    Participants with valgus-type SCFE
    5 participants
    all 5 participants who developed SCFE

    Source sentences

    Summary
    All 5 participants who developed SCFE had received >12 months of treatment and presented with the rare valgus type of SCFE.
    1 context sentence
    Summary · context
    We report 5 participants from two investigator-initiated, single center, phase II, prospective, open label clinical trials of vosoritide (NCT04219007 Basket trial including patients with RASopathies, Aggrecan mutations (ACAN) and NPR2 deficiency and NCT05849389 in girls with Turner syndrome) who developed SCFE.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.